

1 **Supplementary Methods, Jiang et al. 2021**

2 3 **Cells**

4 The Hox cell line was generated by transducing bone marrow cells of C57BL/6 Cas9+ GFP+
5 mice with an estrogen inducible retroviral construct expressing HoxB8 as described in (1,2).
6 Hox cells are immortalized by estrogen-regulated Hoxb8 (ER-Hoxb8) and display a
7 Granulocyte-Monocyte Progenitor (GMP) phenotype, as described in Supplementary Fig. S1A-
8 B. Hox cells were cultured in RPMI-1640 with 10% heat-inactivated fetal bovine serum, 1%
9 penicillin-streptomycin-glutamine, 1 μ M BE, and 25 nM SCF. No cell line authentication was
10 performed to Hox cells.

11 B16-F10 cell is a mouse melanoma cell line, purchased from ATCC that performs
12 authentication and used at a low passage number. Cas9 expressing cells were generated by
13 transducing B16-F10 cells with lentiCas9-Blast lentiviral particles. B16 cells were cultured in
14 RPMI-1640 with 10% serum, and 1% penicillin-streptomycin-glutamine. All cells were
15 confirmed *Mycoplasma* negative before culture.

16 *Trp53* KO Hox and B16-F10 cells were generated by electroporation or transfection,
17 respectively, of a *Trp53* targeting sgRNA (Supplementary Table S2, Genomic Location
18 11:69479559-69479578). To limit artefacts due to selection of specific clones, cells were used
19 as a mixed population strongly dominated by +1 and +2 insertions, and a >95% KO score.
20

21 **Viral preparation and transduction**

22 Lentiviral particles were generated by seeding 2×10^6 HEK293T cells in 10 cm plate in 10
23 ml of DMEM with 10% serum and 1% L-glutamine. After ~24 h of culture the medium was
24 replaced by 5 ml of fresh media. Transfer plasmids (lentiCas9-Blast; or LentiGuide-Puro-P2A-
25 EGFP_mRFPstuf), pMD2.G, and psPAX2 were mixed at 4:5:1 ratio, and transfected using
26 Lyovec according to the manufacturer's protocol. After 12 h, the medium was replaced by 8 ml
27 of DMEM with 30% serum and 1% L-glutamine. After another 36 h, the supernatant containing
28 the virus was collected, centrifuged to remove the cell debris and used to spin infect cells.

29 For ER-Hoxb8 retrovirus preparation, plasmids including ER-Hoxb8 and the EcoPac gag-
30 pol-env were mixed at 1:1 ratio for transfection following the same approach as for generating
31 lentiviral particles.

32 To transduce Hox or B16 cells, the multiplicity of infection (MOI) of the viral particles was
33 tested by infection with serial dilutions of virus particles to find a dilution resulting in a suitable
34 MOI. Virus supernatant was added to each well of 6-well plate containing cells (4×10^5 for Hox
35 cells, and 1×10^5 for B16 cells) with 8 μ g/ml polybrene. The plate was centrifuged at 37°C,
36 1200g (120 min for Hox cells, and 45 min for B16 cells). After 24h, the virus-containing
37 medium was replaced with fresh medium, and the infection rate was measured by the
38 percentage of GFP+ cells if the vector contains GFP. Puromycin selection (10 μ g/ml for HoxB8
39 cells, and 5ug/ml for B16 cells) or Blastidicin selection (10 μ g/ml for B16 cells) was performed
40 for 24 h to remove the non-infected cells.
41

42 **sgRNA design, electroporation and transfection**

43 sgRNAs were designed using the Green Listed software (3,4) utilizing sgRNA design from
44 the Doench mouse library (5). 2'-O-methyl and phosphorothioate stabilized sgRNAs
45 (Supplementary Table S2) were ordered from Sigma-Aldrich or Synthego. Off-target activity
46 was calculated using Cas-OFFinder (<http://www.rgenome.net/cas-offinder/>) (6), and On-target
47 activity was extracted from CHOPCHOP (<https://chopchop.cbu.uib.no/>) (7) by searching for
48 *Ccr1*, or entering the EGFP FASTA sequence from the LentiGuide-Puro-P2A-
49 EGFP_mRFPstuf.

50 For Hox cells, Neon Transfection System was used to perform the electroporation following
51 the manufacturer's instructions (Pulse voltage: 1700 V, Pulse width: 20 ms, Pulse number: 1).
52 100 pmol of sgRNA or siRNA were electroporated into 2×10^5 cells for each electroporation
53 experiment using the Neon Transfection System 10 μ L Kit. For B16 cells, Lipofectamine 2000
54 Transfection Reagent was used following the recommended protocol. 100pmol of sgRNA or
55 siRNA were transfected into 1×10^5 cells for each transfection experiment. The *Trp53* siRNA
56 was typically delivered in the same reaction as the sgRNAs.

57

58 **CRISPR KO genotyping**

59 1×10^5 cells were collected for genomic DNA extraction using DNeasy Blood & Tissue Kit.
60 Primers were designed using Primer-BLAST (Supplementary Table S2), aiming for a 400-1000
61 bp amplicon with the sgRNA target in the middle. Amplicons were gel purified and recovered
62 using Zymoclean Gel DNA Recovery Kit. The PCR products were quantified using Nanodrop
63 and sequenced by Eurofins Genomics. The Sanger sequencing data was subsequently analyzed
64 by ICE (Synthego, <https://ice.synthego.com>).

65

66 **Growth curve characterization**

67 Hox cells were cultured with the following interventions: electroporation with a GFP
68 targeting sgRNA; 0.5 μ g/ml Etoposide; 3 μ M AMG232. The Etoposide and AMG232 were
69 replaced by fresh media after 8 h. The cells were cultured in 6 well plates with 3 ml medium
70 and each day 2 ml medium was exchanged. 80 μ l of cells were taken each day for flow
71 cytometry (BD Accuri) with the existence of CountBright Absolute Counting Beads. The
72 absolute viable cell number was calculated by comparing the events number of viable cells and
73 counting beads in the flow cytometry data.

74

75 **Cloning of sgRNAs into lentiviral transfer plasmid, and CRISPR screens**

76 sgRNAs with overhangs for the LentiGuide transfer plasmid (Supplementary Table S3) were
77 designed using the Green Listed software (3,4) using sgRNA design from the Doench mouse
78 library (5) and, for intergenic controls, the Wang mouse library (8). Individual sgRNAs were
79 ordered from Sigma-Aldrich, and the sgRNA library was ordered from CustomArray as a DNA
80 oligo pool. Cloning was performed using BsmBI cleaved lentiGuide-Puro-P2A-
81 EGFP_mRFPstuf plasmid and the library oligo pool, with NEBuilder HiFi DNA assembly
82 master mix. Endura ElectroCompetent cells were subsequently transformed with the cloned
83 plasmid pool using electroporation (1.0 mm cuvette, 10 μ F, 600 Ohms, 1800 Volts). The
84 electroporated cells were combined and seeded on ten 20 cm LB agar plates with carbenicillin
85 and grown at 37°C overnight. The lentiGuide-Puro-P2A-EGFP_mRFPstuf plasmid makes

86 bacteria red if the stuffer has not been exchanged by a sgRNA, and a few red clones were
87 removed before collecting all other white clones. Plasmids were purified using the EndoFree
88 Plasmid Maxi Kit.

89 The sgRNA cloned lentiGuide-Puro-P2A-EGFP_mRFPstuf was used as transfer plasmid for
90 lentiviral preparation and transduction. The total amount of transduced cells was calculated
91 based on MOI (0.25 for B16 cells, and 0.05-0.1 for Hox cells), aiming for 1000 transduced cells
92 for each sgRNA.

93 The CRISPR library transduced cells were exposed to GFP targeting sgRNA electroporation
94 with or without *Trp53* siRNA, 0.5 µg/ml Etoposide 8 h pulse stimulation, or 3 µM AMG232 8
95 h pulse stimulation.

96 Cells were collected for genomic DNA extraction using the DNeasy Blood & Tissue Kit.
97 Genomic DNA was then amplified using Q5 High-Fidelity DNA Polymerase. Sample-specific
98 barcodes and adapters for Illumina Sequencing similar as described in (9) were introduced at
99 the same time using primers specified in Supplementary Table S4. The final PCR products were
100 gel purified and recovered using the Zymoclean Gel DNA Recovery Kit, and quantified with
101 Qubit 4 Fluorometer using the Qubit dsDNA HS Assay Kit and pooled for next-generation
102 sequencing (Illumina MiSeq v3 run, 2x75bp reads). The raw FASTQ data were analyzed by
103 MAGeCK(10). Read counts from CRISPR screens are found in Supplementary Table S5-6.

104

105 **JAK1/STAT1 signaling assay**

106 Hox cells were cultured with or without mouse Interferon Beta and the Jak1 inhibitor
107 Solcitinib for 7 days. Cells were taken on day 7 for flow cytometry (BD Accuri) with the
108 existence of CountBright Absolute Counting Beads. The absolute viable cell number was
109 calculated by comparing the events number of viable cells and counting beads in the flow
110 cytometry data.

111

112 **Competitive co-culture assay**

113 *Trp53* KO and WT cells were mixed at 1:4 ratio, and subsequently exposed to different
114 interventions: CRISPR - electroporated with sgRNA or transduced with lentivirus and culture
115 for 7 days; or exposed to Etoposide (0.5 µg/ml for 8h) or AMG232 (3 µM for Hox cells, 4 µM
116 for B16 cells for 8h) and cultured for 7 days; or cultured with Cobalt(II) chloride (CoCl₂, 10-
117 20 µg/ml) for 7 days. For hypoxia experiments, Hox cells were cultured in a 1% O₂ for 7 days,
118 in Baker InvivoO2 Physiological Cell Culture Workstations. For *in vivo* experiments, B16 cells
119 were transfected with a *Ccr1* targeting sgRNA (Supplementary Table S2) or control, and
120 directly injected (5*10⁵ cells) s.c. into C57BL/6 mice, and tumors collected after 21 days. The
121 proportion of *Trp53* KO cells was subsequently quantified by sequencing as described in
122 CRISPR KO genotyping.

123 Different p53 related inhibitors were added during culture: *Trp53* ON-TARGETplus siRNA
124 SMARTPool, KU55933 (100 ng/ml for B16, 10 ng/ml for Hox), VE821 (50 ng/ml), Pifithrin-
125 µ (2 µg/ml for B16, 200 ng/ml for Hox), Cyclic Pifithrin-α (700 ng/ml for B16, 70 ng/ml for
126 Hox), C646 (1 µg/ml), AZD2461 (250 ng/ml), LJI308 (2 ng/ml), Z-VAD-FMK (50 µM).
127 siRNA was delivered to cells 1 day before CRISPR/Etoposide/AMG232 exposure (100 pmol
128 of siRNA electroporated into 2x10⁵ Hox cells, or transfected into 1x10⁵ B16 cells), or together
129 with sgRNA for the transfection/electroporation groups. Other inhibitors were added to cell

130 culture media 1 day before CRISPR/Etoposide/AMG232 exposure and cultured for 7 days.
131 Cells were then collected for *Trp53* KO genotyping.

132

133 **Flow Cytometry Analysis**

134 Fresh bone marrow cells from C57BL/6 Cas9+ GFP+ mice and Hox cells were stained with
135 the following antibodies (further described in Supplementary Table S1): FITC Rat anti-Mouse
136 CD34 (1:500), PE anti-mouse CD150 (1:200), PerCP/Cyanine5.5 anti-mouse Ly-6A/E (1:200),
137 APC anti-mouse CD117 (1:500), APC/Cyanine7 anti-mouse CD16/32 (1:500), Biotin anti-
138 mouse Lineage Panel (1:100), BV421 Streptavidin (1:1000), LIVE/DEAD Fixable Aqua Dead
139 Cell Stain Kit (1:2000). After 30 min of staining, the cells were washed and analyzed by flow
140 cytometry (BD FACSVerse). FACS FCS files were analyzed by FlowJo version 10 (FlowJo,
141 LLC).

142

143 **Analysis of data from the Depmap portal**

144 SgRNA enrichment (CRISPR (Avana) Public 20Q4 release), mutation profile (Mutation
145 Public 20Q4 release), drug sensitivity (PRISM Repurposing Primary Screen 19Q4 release), and
146 mRNA expression levels (Expression Public 20Q4 release) was extracted December 13th, 2020
147 from the Depmap portal (<https://depmap.org/portal/>) (11-15). Correlation analysis was
148 performed with the Depmap data explorer tool. Connectivity maps were generated using the
149 geneMANIA plugin for Cytoscape (16,17). tSNE plots were made with the Rtsne package
150 (<https://github.com/jkrijthe/Rtsne>) to analyze the cluster and ggplot2
151 (<https://github.com/tidyverse/ggplot2>) to visualize the data, or tSNE-online
152 (<https://github.com/jefworks/tsne-online>). The “ENCODE and ChEA Consensus TFs from
153 ChIP-X” functionality of Enrichr (<https://maayanlab.cloud/Enrichr/index.html>) (18,19) was
154 used to identify transcription factor binding to gene sets.

155

156 **References**

- 157 1. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps MP. Quantitative production of
158 macrophages or neutrophils ex vivo using conditional Hoxb8. *Nat Methods* **2006**;3:287-93
- 159 2. Panda SK, Wigerblad G, Jiang L, Jimenez-Andrade Y, Iyer VS, Shen Y, *et al.* IL-4 controls
160 activated neutrophil Fcγ2b expression and migration into inflamed joints. *Proc Natl*
161 *Acad Sci U S A* **2020**;117:3103-13
- 162 3. Panda SK, Boddul SV, Jimenez-Andrade GY, Jiang L, Kasza Z, Fernandez-Ricaud L, *et al.* Green
163 listed-a CRISPR screen tool. *Bioinformatics* **2017**;33:1099-100
- 164 4. Iyer VS, Jiang L, Shen Y, Boddul SV, Panda SK, Kasza Z, *et al.* Designing custom CRISPR libraries
165 for hypothesis-driven drug target discovery. *Comput Struct Biotechnol J* **2020**;18:2237-46
- 166 5. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, *et al.* Optimized sgRNA
167 design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol*
168 **2016**;34:184-91
- 169 6. Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential
170 off-target sites of Cas9 RNA-guided endonucleases. *Bioinformatics* **2014**;30:1473-5
- 171 7. Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. CHOPCHOP v3:
172 expanding the CRISPR web toolbox beyond genome editing. *Nucleic Acids Res*
173 **2019**;47:W171-W4

- 174 8. Wang T, Yu H, Hughes NW, Liu B, Kendirli A, Klein K, *et al.* Gene Essentiality Profiling Reveals
175 Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras. *Cell* **2017**;168:890-903
176 e15
- 177 9. Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, *et al.* Genome-
178 scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nat Protoc*
179 **2017**;12:828-63
- 180 10. Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, *et al.* MAGeCK enables robust identification of
181 essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome biology*
182 **2014**;15:554
- 183 11. Dempster JM, Rossen J, Kazachkova M, Pan J, Kugener G, Root DE, *et al.* Extracting Biological
184 Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines. *bioRxiv*
185 **2019**:720243
- 186 12. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, *et al.* Computational
187 correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in
188 cancer cells. *Nat Genet* **2017**;49:1779-84
- 189 13. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, *et al.* Next-
190 generation characterization of the Cancer Cell Line Encyclopedia. *Nature* **2019**;569:503-8
- 191 14. Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer
192 dependency map. *Nat Rev Genet* **2015**;16:373-4
- 193 15. Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, *et al.* High-throughput
194 identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell
195 lines. *Nat Biotechnol* **2016**;34:419-23
- 196 16. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, *et al.* GeneMANIA update
197 2018. *Nucleic Acids Res* **2018**;46:W60-W4
- 198 17. Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, *et al.* GeneMANIA
199 Cytoscape plugin: fast gene function predictions on the desktop. *Bioinformatics*
200 **2010**;26:2927-8
- 201 18. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, *et al.* Enrichr: interactive and
202 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **2013**;14:128
- 203 19. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, *et al.* Enrichr: a
204 comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res*
205 **2016**;44:W90-7